Article Details
Retrieved on: 2024-04-06 20:25:54
Tags for this article:
Click the tags to see associated articles and topics
Summary
The FDA approved Enhertu, a HER2-targeted antibody-drug conjugate, for patients with unresectable or metastatic HER2-positive solid tumors. Used after other therapies, it addresses the need for effective treatments in varied cancer types, but may harm fetuses during pregnancy.
Article found on: www.cancerhealth.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here